Cosmetic Surgery With Autoimmune Disease: The Drug List Nobody Times Correctly

Somewhere on every cosmetic surgery intake form is a box for medical conditions and a blank line for medications. A patient with rheumatoid arthritis, psoriasis, lupus, Crohn's disease, or any of the several dozen conditions treated with immune suppressing drugs writes the diagnosis in the box, lists the drug on the line, and moves on. In most practices, that is where the conversation about cosmetic surgery with autoimmune disease begins and ends.

It should not be. The relevant question is almost never the diagnosis. It is which drug, at what dose, on what interval, and when the last dose was given relative to the day of the operation. Immune suppression and wound healing pull against each other in a way that is well characterized, and the field that treats these patients has written down what to do about it. Aesthetic surgery has largely not read it.

The published guideline is about knee replacements, not facelifts

The short answer: the American College of Rheumatology and the American Association of Hip and Knee Surgeons publish a joint guideline on managing antirheumatic medication around elective joint replacement, and it is the closest thing to a standard that exists. No equivalent document covers elective aesthetic surgery.

The 2022 ACR and AAHKS guideline, an update of the 2017 version, sorts the drugs into groups and gives instructions that are unusually concrete for a guideline.

• Continue through surgery: conventional agents including methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and apremilast. The evidence does not support stopping them, and stopping them invites a disease flare during recovery.
• Withhold and time the surgery to the dosing cycle: biologics, meaning the TNF inhibitors, interleukin blockers, and related injected or infused agents. The recommendation is to schedule the operation at the end of the dosing interval, so that surgery falls at the point of lowest drug effect rather than the point of highest.
• Withhold briefly: JAK inhibitors such as tofacitinib, held three days before surgery in the 2022 update, shortened from the seven days advised in 2017.
• Restart on wound criteria, not on a date: biologics resume roughly fourteen days after surgery, and only when the wound looks satisfactory, with sutures out, no drainage, no swelling or erythema, and no infection anywhere else.
• Do not stress dose steroids reflexively: for patients on chronic glucocorticoids for a rheumatic condition, the guidance is to continue the usual daily dose rather than administer the large supraphysiologic doses that were standard practice for decades.
• Lupus is handled by severity: in severe systemic lupus, agents such as mycophenolate, azathioprine, tacrolimus, and cyclosporine are continued, because the risk of a flare outweighs the perioperative risk. In non severe disease, they are withheld.

That structure is worth understanding even though the population studied was joint replacement patients. The logic transfers cleanly. What does not transfer is the assumption of medical necessity, and that difference cuts in the patient's favor.

"

A knee replacement is scheduled around the patient's pain. An elective cosmetic operation can be scheduled around the patient's dosing calendar. That flexibility is the single largest safety advantage aesthetic surgery has here, and it is routinely wasted.

"

Why the infection and healing signal exists at all

The short answer: TNF inhibitors and similar agents suppress exactly the inflammatory cascade that closes a wound, and observational data in orthopedic surgery has repeatedly linked their use around the time of surgery to higher surgical site infection and wound complication rates.

Healing runs in phases, and the first one is inflammation. Neutrophils and macrophages clear contamination and debris, then signal the fibroblasts that lay down collagen. Drugs designed to blunt that signaling in a joint blunt it in an incision too. The clinical literature in arthroplasty and inflammatory bowel disease surgery is observational rather than randomized, and effect sizes vary between studies, but the direction has been consistent enough that the guideline recommends holding these agents rather than waiting for better data.

Chronic corticosteroids are the more visible problem, because you can often see them before the patient speaks. Long term prednisone thins the dermis, reduces collagen deposition, and increases the risk of wound dehiscence and infection. It also produces the fragile, translucent skin that makes undermining and closure harder in facial and body contouring surgery. Supplemental vitamin A has been proposed for years as a way to counteract steroid impaired healing, and it has support in animal work and limited clinical data, but it is not a settled intervention and no patient should treat it as a workaround for operating on a dose that should have been reduced first.

This sits alongside the other quiet, protocol level decisions that determine complication rates: the antibiotic decision, glycemic control, and the supplement stop list. Immune suppressing medication belongs on that list and rarely appears on it.

The disease specific traps that have nothing to do with the drug

The short answer: several autoimmune conditions carry a structural problem that changes which operation is reasonable, independent of medication, and each one maps to a procedure aesthetic surgeons perform constantly.

Sjogren's syndrome and eyelid surgery. Sjogren's destroys tear production. Upper and lower blepharoplasty removes tissue that protects the ocular surface and can produce even mild lagophthalmos, meaning incomplete closure. In a patient with a normal tear film that is a temporary nuisance. In a patient with severe dry eye it can mean exposure keratopathy and lasting corneal damage. Tear film assessment before eyelid surgery in these patients is not optional, and for some of them the honest answer is no.

Scleroderma and facial surgery. Systemic sclerosis produces tight, poorly vascularized skin, impaired healing, digital ulceration, and microstomia. Elective facial procedures in active disease are a poor bet, and surgeons who operate anyway tend to learn the same lesson twice.

Lupus and two separate risks. Cutaneous photosensitivity makes laser and light based resurfacing a more careful conversation, an issue that overlaps with the pigment questions covered in procedures on deeper skin tones. Separately, a meaningful subset of lupus patients carry antiphospholipid antibodies, which raise thrombosis risk substantially and change the entire calculation around clot prevention for a long operation.

Psoriasis and the incision line. The Koebner phenomenon means new psoriatic plaques can appear at sites of skin trauma, including surgical incisions. A patient with unstable, actively spreading disease is a patient whose scar may behave in ways that no amount of scar care will fix.

Long standing rheumatoid arthritis and the airway. Cervical spine instability at the atlantoaxial joint was a classic anesthetic concern in severe, poorly controlled disease. Modern treatment has made it much less common, which is precisely why it can be overlooked in the patient who has had the disease for thirty years.

The handoff is where this actually fails

The short answer: the specialist who prescribes the drug does not know the surgery date, the aesthetic surgeon does not manage the drug, and in most cases nobody is formally assigned to bridge that gap.

In a hospital, this is a preoperative clinic function. Someone reviews the medication list against the procedure and makes calls. Elective aesthetic surgery frequently runs without that layer. The patient is the only person holding both pieces of information, and patients reasonably assume that writing a drug on a form means somebody acted on it.

The failure modes are predictable. A patient stops methotrexate unnecessarily and flares in week two of recovery, when they are already dealing with the emotional and physical low point of healing. A patient continues a biologic and has an infusion four days before an abdominoplasty. A patient on chronic prednisone gets a long, tension bearing closure planned as though their skin were normal. None of these require bad judgment. They require only that nobody owned the question. The same ownership gap runs through antiviral prophylaxis and preoperative optimization generally.

Worth saying plainly: an autoimmune diagnosis is not a bar to cosmetic surgery. Most of these patients can have most of these operations. What changes is that the date is no longer arbitrary, the medication plan needs an author, and a few specific disease and procedure pairings deserve a harder look than the intake form gives them.

The honest summary

The evidence base here is imperfect and mostly borrowed. The ACR and AAHKS guideline was built for joint replacement, the infection data is observational, and there is no aesthetic surgery specific document to point at. That is an argument for adapting the best available framework, not for ignoring the question, which is the current default in a great many practices.

Three things are worth carrying out of this.

The drug and its dosing interval matter more than the diagnosis. Conventional agents such as methotrexate and hydroxychloroquine are generally continued. Biologics are generally held with the operation timed to the end of the dosing cycle and restarted on wound criteria rather than on a calendar date. JAK inhibitors get a short hold. Chronic steroids are continued at the usual dose rather than stress dosed, and they change how the skin will behave.

Elective timing is an advantage you should insist on using. Unlike someone waiting on a hip, you can move your surgery date to the low point of your dosing cycle at no medical cost. If a practice will not do that, it is telling you that the schedule matters more than the plan.

And a handful of conditions change the operation itself, not just the medication. Dry eye and eyelid surgery, scleroderma and facial procedures, antiphospholipid antibodies and long body contouring cases, unstable psoriasis and incision lines. These are worth raising specifically at the second consultation, because a surgeon who has thought about them will answer immediately, and a surgeon who has not will reassure you instead.